Skip to main content

and
  1. No Access

    Article

    Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study

    Fourteen patients suffering from advanced colorectal (n = 7), pancreatic (n = 4) or gastric (n = 3) carcinomas received treatment with microencapsulated octreotide pamoate 90 mg i.m. every 4 weeks (n = 4), 160...

    SI Helle, J Geisler, JP Poulsen, K Hestdal, K Meadows in British Journal of Cancer (1998)